Date: 2011	.7.10
Date	Total and Diena
Manuscript Title: High 6	expression of CD73 contributes to poor prognosis of clear-cell renal cell carcinoma by promoting
cell proliferation and m	igration
Manuscript number (if I	(nown): TCR-22-544
In the interest of transp	arency, we ask you to disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	元	Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	None	
4	Consulting fees	_X_None	
5	Payment or honoraria for	<u>X</u> None	WELL HAR RETURNED TO THE PARTY OF THE PARTY

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data	X_None	
	Safety Monitoring Board or		
-	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_None	
11	Stock or stock options	_X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
-	services		
13	Other financial or non- financial interests	_X_None	

CONSTRUCTION OF THE PARTY OF TH

None		

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022.7.13		
	Dong	Jiang	prognosis of clear-cell renal cell carcinoma by promoting
Manuscript Title	: High expressio	of CD73 contributes to poor p	prognosis of clear-cell renal cell carcinoma 27
cell proliferation	and migration		
Manuscript num	nber (if known):	CR-22-544	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	分析	Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Timore	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	at 36 months
3	Royalties or licenses		
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events	
6	Payment for expert testimony	X_None
7	Support for attending meetings and/or travel	_X None
8	Patents planned, issued or pending	X_None
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_None
11	Stock or stock options	X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None
13	Other financial or non- financial interests	None

Please summarize the above conflict of interest in the following box:

None.	

Please place an "X" next to the following statement to indicate your agreement:

1	Date: 2022. 7	. 10	
,	Your Name: Xi	Chu	
ı	Manuscript Title: High express	sion of CD73 contributes to	poor prognosis of clear-cell renal cell carcinoma by pron
(cell proliferation and migratio	n	
1	Manuscript number (if known): TCR-22-544	
r	elated to the content of your parties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a o so.
	he following questions apply nanuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current
m In	nedication, even if that medic	pport for the work reported in the past 36 months. Name all entities with	ed in this manuscript without time limit. For all other it
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
No.		Time frame: Since the initia	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
SM	PANCED VERNOUS ASSESSMENT OF THE PARCET OF T		
	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	t 36 months
	Royalties or licenses	X_None	
	Consulting fees	X_None	

Payment or honoraria for

☆ None

	lectures, presentations,	
	speakers bureaus, manuscript writing or educational events	
6	Payment for expert testimony	_X_None
7	Support for attending meetings and/or travel	_X_None
3		
8	Patents planned, issued or pending	_X_None
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_None
11	Stock or stock options	X_None
12	Receipt of equipment, materials, drugs, medical	X_None
	writing, gifts or other services	
13	Other financial or non- financial interests	

None		

Please place an "X" next to the following statement to indicate your agreement:

	ICMJE DISC	LOSURE FORM
Date:	0	
Variablemen MA 1 1	sion of CD73 contributes to	poor prognosis of clear-cell renal cell carcinoma by promoting
related to the content of your	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment i. If you are in doubt about whether to list a o so.
The following questions apply manuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>
to the epidemiology of hypert medication, even if that medication	ension, you should declar cation is not mentioned in pport for the work report	e defined broadly. For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items,
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initi	al planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
Grants or contracts from	Time frame: pas	st 36 months
antitudif not indicated		

in item #1 above).

Consulting fees

3

4

Royalties or licenses

any entity (if not indicated

Payment or honoraria for

X None

X_None

∠None

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

riease summarize the above conflict of litter

None		

Please place an "X" next to the following statement to indicate your agreement:

Date: 2072.7.13	
Your Name: Hao Qi	
Manuscript Title: High expression of cell proliferation and migration	CD73 contributes to poor prognosis of clear-cell renal cell carcinoma by promoting
Manuscript number (if known): TCR-2	2-544

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	多。据长期长期,但1000000000000000000000000000000000000	Time frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	BANK BURNEY TO BE SOUTH TO	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	3000
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Please summarize the above conflict of interest in the following box:

None		

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022.7.10		
Your Name: Xiang	Wu	
	sion of CD73 contributes t	o poor prognosis of clear-cell renal cell carcinoma by promotin
Manuscript number (if knows		
parties whose interests may to transparency and does not relationship/activity/interest	r manuscript. "Related" me be affected by the content necessarily indicate a bias , it is preferable that you d	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so. hips/activities/interests as they relate to the current
to the epidemiology of hyper medication, even if that medi	tension, you should declar ication is not mentioned in upport for the work report	e defined broadly. For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. The defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
AND THE PARTY OF T	Time frame: Since the initia	al planning of the work

		relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events	
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

commentation and the letters were as a second

Please summarize the above conflict of interest in the following box:

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:	
Your Name: Yuxin Tang	
Manuscript Title: High expression of CD73 contributes to poor prog	nosis of clear
Manuscript Title: High expression of CD73 contributes to poor prog cell proliferation and migration	renal cell carcinoma by promoting
Manuscript number (if known): TCR-22-544	

2400 7 .2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

WHILE		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	这是我们是一个人的。	Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time for	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pasNone	t 36 months
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	- 51 . To
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None None	

Please summarize the above conflict of interest in the following box:

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022.7. 15 Your Name: Yingbo DAI		
Date: DAT		
Your Name: 9ing 60 0131	contributes to poor prognosis of al	

Manuscript Title: High expression of CD73 contributes to poor prognosis of clear-cell renal cell carcinoma by promoting

cell proliferation and migration

Manuscript number (if known): TCR-22-544

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	《科学》	Time frame: pas	st 26 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	SC SO MONETS
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus,	
Pall.	manuscript writing or educational events	
5	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
.2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

none.		

Please place an "X" next to the following statement to indicate your agreement:

<u>λ</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.